Kiora Pharmaceuticals Inc (KPHMW)
KPHMW is quoted over the counter, not listed on an exchange. Kiora Pharmaceuticals Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Profile
| Field | Value |
|---|---|
| Ticker | KPHMW, quoted over the counter |
| SEC CIK | 0001372514 |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Encinitas, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The factors described above have caused management to determine there is substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $5.6M cash; operating cash flow -$1.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 4,424,387 (2026-11-10); 3,677,935 a year earlier; 7,689,240 three years earlier. 3y figure adjusted for splits (1-for-9 overall). | Cover page 2026-11-10 |
| Reverse splits, 3 years | 1; latest 1-for-9 on 2024-06-11 | Source 2024-06-11 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Haskell & White LLP, Irvine, California, United States | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.0M | -$1.7M | -$558K | $5.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$2.1M | -$1.9M | $7.1M | No debt tags | Needs four quarters | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | Not filed | -$2.4M | -$3.2M | $11.0M | No debt tags | Needs four quarters | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $0 | -$6.5M | -$2.2M | $8.7M | No debt tags | $0 | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $0 | $27K | -$1.3M | $5.5M | No debt tags | $0 | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $0 | -$2.2M | -$3.8M | $1.0M | No debt tags | $0 | 10-Q 2025-08-08 |
| Q1 2025 2025-03-31 | $0 | -$2.2M | -$2.7M | $3.8M | No debt tags | $20K | 10-Q 2025-05-09 |
| Q4 2024 2024-12-31 | $0 | -$4.2M | -$2.3M | $3.8M | No debt tags | $16.0M | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-05-28 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 929 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier